Home About us Contact
|
Home About us Contact | ||
|
|
||
Rapid Adoption (rapid + adoption)
Selected AbstractsNational AIDS Commissions in Africa: Performance and Emerging ChallengesDEVELOPMENT POLICY REVIEW, Issue 2 2009Erasmus Morah This article consolidates and expands on evidence on how National AIDS Commissions (NACs) in sub-Saharan Africa are measuring up to expectations that drove their rapid adoption across the continent. While their overall performance seems reasonably good, most NACs still lack adequate power and incentive structures to hold line ministries accountable, a key requirement for co-ordinating activities and mainstreaming HIV-AIDS across the public sector. Second-generation African NACs urgently need the authority and institutional stature to effectively co-ordinate the channelling of the larger funds now available through government bureaucracy. The evolution of the epidemic also imposes requirements different from those when the current NAC architecture was crafted. [source] The role of medical simulation: an overview,THE INTERNATIONAL JOURNAL OF MEDICAL ROBOTICS AND COMPUTER ASSISTED SURGERY, Issue 3 2006Kevin Kunkler Abstract Robotic surgery and medical simulation have much in common: both use a mechanized interface that provides visual "patient" reactions in response to the actions of the health care professional (although simulation also includes touch feedback); both use monitors to visualize the progression of the procedure; and both use computer software applications through which the health care professional interacts. Both technologies are experiencing rapid adoption and are viewed as modalities that allow physicians to perform increasingly complex minimally invasive procedures while enhancing patient safety. A review of the literature and industry developments concludes that medical simulators can be useful tools in determining a physician's understanding and use of best practices, management of patient complications, appropriate use of instruments and tools, and overall competence in performing procedures. Future use of these systems depends on their impact on patient safety, procedure completion time and cost efficiency. The sooner simulation training can be used to support developing technologies and procedures, the earlier, and typically the better, the results. Continued studies are needed to identify and ensure the ongoing applicability of these systems for both training and certification. Copyright © 2006 John Wiley & Sons, Ltd. [source] New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapiesASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Issue 1 2010Thean Hsiang TAN Abstract Advances in understanding the biology and genetics of renal-cell carcinomas have led to the development of novel targeted therapies for the treatment of metastatic renal-cell cancer. Previously the systemic approaches were limited to cytokine therapies that were modest in their clinical benefits and at the expense of significant toxicities. Investigational treatments with allogeneic bone marrow transplantation were equally toxic and resulted in significant morbidity and mortality. The development of targeted therapy has revolutionized the treatment of metastatic renal-cell cancer with more meaningful outcomes. This review aims to provide a detailed discussion of the clinical benefits of targeted therapies such as sunitinib, sorafenib, temsirolimus, everolimus, bevacizumab, and some of the newer agents in clinical trial development. The efficacy of these compounds in terms of response, survival and clinical benefit are explored as well as their toxicities. The role of surgery in metastatic renal-cell carcinoma is reviewed in the context of cytoreductive therapy and resection of solitary and oligometastatic disease. Ongoing studies in the adjuvant setting following curative resection are also reviewed. The availability of targeted therapies has led to their rapid adoption as frontline therapy over traditional cytokine therapy, thus bringing more optimistic and hopeful therapeutic options in a condition where historically, systemic treatments have been relatively unsatisfactory and disappointing. [source] Disposable bioprocessing: The future has arrivedBIOTECHNOLOGY & BIOENGINEERING, Issue 2 2009Govind Rao Abstract Increasing cost pressures are driving the rapid adoption of disposables in bioprocessing. While well ensconced in lab-scale operations, the lower operating/ validation costs at larger scale and relative ease of use are leading to these systems entering all stages and operations of a typical biopharmaceutical manufacturing process. Here, we focus on progress made in the incorporation of disposable equipment with sensor technology in bioprocessing throughout the development cycle. We note that sensor patch technology is mostly being adapted to disposable cell culture devices, but future adaptation to downstream steps is conceivable. Lastly, regulatory requirements are also briefly assessed in the context of disposables and the Process Analytical Technologies (PAT) and Quality by Design (QbD) initiatives. Biotechnol. Bioeng. 2009;102: 348,356. © 2008 Wiley Periodicals, Inc. [source] | ||||||||||